目次

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Drug Overdose - Overview
Drug Overdose - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Drug Overdose - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Overdose - Companies Involved in Therapeutics Development
Amphastar Pharmaceuticals Inc
Avior Bio Inc
Clear Scientific LLC
Crossject SA
Egetis Therapeutics AB
Emergent BioSolutions Inc
Enalare Therapeutics Inc
Fab'entech SA
Hepione Therapeutics Inc
Icure Pharmaceutical Inc
InterveXion Therapeutics LLC
Klaria Pharma Holding AB
Mucodel Pharma LLC
Nasus Pharma Ltd
Opiant Pharmaceuticals Inc
Orexo AB
ResQ Pharma Inc
Sparian Biosciences Inc
Vallon Pharmaceuticals Inc
Vernalis R&D Ltd
Worphmed Srl
Drug Overdose - Drug Profiles
Antibody for Drug Overdose, Opioid Addiction and Poisoning - Drug Profile
Product Description
Mechanism Of Action
drinabant - Drug Profile
Product Description
Mechanism Of Action
History of Events
ENA-001 - Drug Profile
Product Description
Mechanism Of Action
IXTf-250 - Drug Profile
Product Description
Mechanism Of Action
IXTM-200 - Drug Profile
Product Description
Mechanism Of Action
History of Events
melatonin - Drug Profile
Product Description
Mechanism Of Action
History of Events
nalmefene - Drug Profile
Product Description
Mechanism Of Action
History of Events
nalmefene - Drug Profile
Product Description
Mechanism Of Action
History of Events
nalmefene - Drug Profile
Product Description
Mechanism Of Action
naloxone - Drug Profile
Product Description
Mechanism Of Action
History of Events
naloxone - Drug Profile
Product Description
Mechanism Of Action
History of Events
naloxone - Drug Profile
Product Description
Mechanism Of Action
naloxone - Drug Profile
Product Description
Mechanism Of Action
History of Events
naloxone - Drug Profile
Product Description
Mechanism Of Action
History of Events
naloxone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
naloxone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
naloxone hydrochloride 1 - Drug Profile
Product Description
Mechanism Of Action
naloxone. - Drug Profile
Product Description
Mechanism Of Action
History of Events
OPNT-006 - Drug Profile
Product Description
Mechanism Of Action
History of Events
physostigmine - Drug Profile
Product Description
Mechanism Of Action
PP-100 - Drug Profile
Product Description
Mechanism Of Action
SBS-371 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule for Acute Opioid Overdosage - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule for Drug Overdose and Drug Toxicity - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Alzheimer's Disease and Drug Overdose - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Substance Abuse and Drug Overdose - Drug Profile
Product Description
Mechanism Of Action
V-24343 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Vaccine for Drug Overdose - Drug Profile
Product Description
Mechanism Of Action
Vaccine for Drug Overdose - Drug Profile
Product Description
Mechanism Of Action
Drug Overdose - Dormant Projects
Drug Overdose - Discontinued Products
Drug Overdose - Product Development Milestones
Featured News & Press Releases
Apr 01, 2022: Anebulo Pharmaceuticals doses more than half of the subjects in part A of a phase 2 clinical trial and provides guidance on IND submission
Feb 08, 2022: Teva agrees to pay $225m to settle opioid claims in Texas
Jan 03, 2022: Anebulo Pharmaceuticals announces initiation of phase 2 clinical study evaluating ANEB-001 for the treatment of acute cannabinoid intoxication
Dec 20, 2021: Klaria Pharma initiates clinical study with Naloxon Alginate Film
Dec 02, 2021: Klaria Pharma receives approval to initiate clinical Phase 1 trial of Naloxone Alginate Film
Nov 16, 2021: Orexo announces positive results from pivotal trial for its leading pharmaceutical pipeline asset OX124
Oct 22, 2021: Klaria Pharma announces approval by the United Stated Patent and Trademark Office of a new patent application covering naloxone alginate film
Oct 13, 2021: Anebulo Pharmaceuticals announces issuance of U.S. patent covering use of ANEB-001 for the treatment of acute Cannabinoid overdose
Sep 13, 2021: Anebulo Pharmaceuticals announces completion of manufacturing of ANEB-001 capsules for upcoming phase 2 clinical trial
Jul 16, 2021: Orexo's flagship pharmaceutical pipeline asset OX124 enters pivotal trial
Apr 13, 2021: Nasus Pharma announces positive results in pivotal trial of FMXIN001 Naloxone powder-based nasal spray for the treatment of opioid overdose
Feb 08, 2021: Opiant Pharmaceuticals announces first patient dosed in confirmatory pharmacokinetic study assessing OPNT003, nasal nalmefene, for the treatment of opioid overdose
Feb 05, 2021: Klaria announces patent approval in Europe of a new product patent covering Naloxone Alginate Film
Jan 29, 2021: Orexo expects FDA filing of OX124 mid 2022
Jan 27, 2021: Orexo strengthens IP rights for overdose rescue drug OX124
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Drug Overdose, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Drug Overdose - Pipeline by Amphastar Pharmaceuticals Inc, 2022
Drug Overdose - Pipeline by Avior Bio Inc, 2022
Drug Overdose - Pipeline by Clear Scientific LLC, 2022
Drug Overdose - Pipeline by Crossject SA, 2022
Drug Overdose - Pipeline by Egetis Therapeutics AB, 2022
Drug Overdose - Pipeline by Emergent BioSolutions Inc, 2022
Drug Overdose - Pipeline by Enalare Therapeutics Inc, 2022
Drug Overdose - Pipeline by Fab'entech SA, 2022
Drug Overdose - Pipeline by Hepione Therapeutics Inc, 2022
Drug Overdose - Pipeline by Icure Pharmaceutical Inc, 2022
Drug Overdose - Pipeline by InterveXion Therapeutics LLC, 2022
Drug Overdose - Pipeline by Klaria Pharma Holding AB, 2022
Drug Overdose - Pipeline by Mucodel Pharma LLC, 2022
Drug Overdose - Pipeline by Nasus Pharma Ltd, 2022
Drug Overdose - Pipeline by Opiant Pharmaceuticals Inc, 2022
Drug Overdose - Pipeline by Orexo AB, 2022
Drug Overdose - Pipeline by ResQ Pharma Inc, 2022
Drug Overdose - Pipeline by Sparian Biosciences Inc, 2022
Drug Overdose - Pipeline by Vallon Pharmaceuticals Inc, 2022
Drug Overdose - Pipeline by Vernalis R&D Ltd, 2022
Drug Overdose - Pipeline by Worphmed Srl, 2022
Drug Overdose - Dormant Projects, 2022
Drug Overdose - Discontinued Products, 2022

List of Figures
Number of Products under Development for Drug Overdose, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022